Cure My Disease

Don't miss your cure!

 Log in / Sign up

Experimental shot aims to rev up immune system against advanced cancers

NCT ID NCT06587295

Recruiting now Disease control Sponsor: National Cancer Centre, Singapore Source: ClinicalTrials.gov ↗

First seen Jul 15, 2026 · Last updated Jul 16, 2026 · Updated 1 time

Summary

This phase 1 trial tests an experimental drug called ACM-CpG, given as a shot into the muscle, in people with advanced solid tumors that have not responded to standard immunotherapy. The drug is designed to activate the immune system to attack tumors. The study aims to find the safest dose and look for early signs that the treatment can shrink or control tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
an experimental immunotherapy called ACM-CpG, given as an intramuscular injection
What this could lead to
If successful, this could lead to a new treatment option for advanced solid tumors that boosts the immune system to fight cancer.
What could go wrong
This is an early phase 1 trial with only 40 participants, so safety and effectiveness are not yet proven. The treatment may cause side effects or not work as hoped.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

metastatic malignant neoplasm neoplasm Neoplasm Metastasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMOR METASTATIC SOLID TUMOR

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • National Cancer Centre, Singapore

    RECRUITING

    Singapore, 168583, Singapore

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.